Enveda raises $311m and Basecamp Research $140m for AI drug discovery

Sep 23, 2026 · Issue 8 · 13 sources, 13 articles

Enveda Biosciences has closed a $311m Series E round to fund clinical trials of nature-derived, AI-discovered drug candidates. Basecamp Research raised $140m; the news appeared on 23 September.

Who is affected and how

pharmaceuticals

The inflow of capital supports AI biotechs' move into the clinical stage, so competitor monitoring should track these candidates too.

Sources

• Enveda’s $311m Series E to fund AI-driven drug discoverybioxconomy · Sep 23, 2026
• AI drug-discovery firm Enveda raises $311Mbizwest · Sep 23, 2026
• Enveda raises $311M Series E to scale AI drug discoverydealroom · Sep 23, 2026
• Enveda Raises $311M to Scale AI Drug Discovery and Advance Clinical Pipelinekonsulteer · Sep 25, 2026
• AI Natural-Medicine Biotech Enveda Raises $311M Series E - WOWTALEen.wowtale.net · Sep 26, 2026
• Enveda secures $311M to bring more nature-derived AI drugs into clinical trialstechcrunch · Sep 23, 2026
• Enveda secures $311M to bring more nature-derived AI drugs into clinical trials | TechCrunchtechcrunch.com · Sep 23, 2026
• Enveda secures $311M to bring more nature-derived AI drugs into clinical trials | TechnologyTangletechnologytangle.com · Sep 23, 2026

Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.